VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 18, 2011) -[ RepliCel Life Sciences Inc. ](the "Company" or "RepliCel") (OTCBB:REPCF) announces that [ Standard & Poor's ] has commenced [ Factual Stock Report coverage on RepliCel Life Sciences, Inc ]. Updated weekly, this factual information will be accessible on an ongoing basis to a wide audience of Buy and Sell-side investors, helping them understand RepliCel's fundamentals and business prospects. Millions of self-directed investors will also have access to the report via their e-brokerage accounts.

David Hall, CEO and President of RepliCel Life Sciences Inc., stated, "RepliCel is committed to being transparent in all its business activities. By partnering with Standard & Poor's, a worldwide leader of financial market intelligence, we are able to provide investors with up-to-date, non-bias investment information."

RepliCel's company information will also be available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their information disseminated to users of Standard & Poor's MarketScope Advisor. This internet-based research engine is used by more than 100,000 investment advisors. A public version of the site is available at [ http://advisor.marketscope.com ].

Furthermore, RepliCel's company information will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of RepliCel will be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in up to 38 states under their Blue Sky Laws.

About RepliCel Life Sciences

The Company has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world's first minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel™ procedure has been developed over the past nine years by the Company's recognized research scientists and medical experts – specialists in the fields of hair growth, hair biology and dermatology. Additional information on RepliCel is available at [ www.replicel.com ].

Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

Notice Regarding Forward-Looking Statements

This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and can include, without limitation, statements based on current expectations involving a number of risks and uncertainties which are not guarantees of future performance of the Company such as the statement that the Replicel™ hair cell replication technology has the potential to become the world's first, minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company clinical trials, including that the hair cell replication technology may not work as planned or may not be effective at causing the re-growth of hair follicles or the rejuvenation of damaged, miniaturized follicles; the effects of government regulation on the Company's business; the viability and marketability of the Company's hair cell replication technology; the Company's failure to successfully implement its marketing plan; the development of superior technology by the Company's competitors; the failure of consumers and the medical community to accept the Company's technology as safe and effective; risks associated with the Company's ability to obtain and protect rights to our intellectual property; risks and uncertainties associated with the Company ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance.

Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2010 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at [ www.sec.gov ] and with the Canadian Securities Commission on Sedar at [ www.sedar.com ].